Results
1
-
2
of
2
[DOI: 10.1021/jm201449n]
An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer
,
Investigational New Drugs
[DOI: 10.1007/s10637-014-0147-9]